Receptor News and Research

RSS

Astex fourth quarter total revenues increase to $21.2 million

Astex Pharmaceuticals, Inc., today reported financial results for the fourth quarter and year ended December 31, 2011.

5 Mar 2012

High blood pressure due to stress maybe due to the immune system

If stress is giving you high blood pressure, blame the immune system. T cells, helpful for fighting infections, are also necessary for mice to show an increase in blood pressure after a period of psychological stress, scientists have found.

5 Mar 2012

Cell-based test to discover molecules to treat ER-positive breast cancer

Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.

5 Mar 2012

Concert commences dosing in CTP-499 Phase 2 clinical trial for diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced the initiation of dosing in a Phase 2 clinical trial evaluating CTP-499, an investigational drug for the treatment of diabetic nephropathy, the leading cause of chronic kidney disease (CKD) in the US.

5 Mar 2012

FDA confirms FluCide pre-IND meeting date with NanoViricides

NanoViricides, Inc. announced today that March 29th, 2012 has been confirmed by the US FDA as the date for its initial meeting with the Company's scientists. This pre-IND meeting will focus on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.

5 Mar 2012

Concert, Fast Forward partner to advance new approach to treat spasticity and pain in MS

Concert Pharmaceuticals, Inc. and Fast Forward, LLC, the National Multiple Sclerosis Society's subsidiary devoted to bridging the gap between research and drug development, today announced a new collaboration to fund the preclinical advancement of C-21191, a deuterium-modified subtype-selective GABAA modulator developed by Concert with the therapeutic potential of treating spasticity and pain in multiple sclerosis (MS).

5 Mar 2012

Exelixis initiates cabozantinib and abiraterone phase 1 combination trial in CRPC

Exelixis Inc. today announced the initiation of a phase 1 dose-finding trial of cabozantinib in combination with abiraterone in men with metastatic castration-resistant prostate cancer (CRPC) who have disease progression following treatment with up to two prior chemotherapy regimens.

5 Mar 2012

Researchers identify mechanism by which cannabis affects working memory

A deterioration of working memory is observed in people who consume drugs containing cannabinoid compounds found in cannabis leaves and buds. A team led by Giovanni Marsicano in collaboration with a team led by Xia Zhang, has recently identified the mechanism by which these substances affect working memory.

3 Mar 2012

Pharmacological antagonist can inhibit body's response to cold

Researchers at St. Joseph's Hospital and Medical Center in Phoenix, Arizona, in collaboration with Amgen Inc. and several academic institutions, have discovered a way to block the body's response to cold using a drug. This finding could have significant implications in treating conditions such as stroke and cardiac arrest.

2 Mar 2012

Similar mechanisms drive changes in puberty

It's one of life's special moments: a child finds a fat caterpillar, puts it in a jar with a twig and a few leaves, and awakens one day to find the caterpillar has disappeared and an elegant but apparently lifeless case now hangs from the twig.

1 Mar 2012

HDAC2 enzyme could be a potential target for new Alzheimer's drugs

MIT neuroscientists have shown that an enzyme overproduced in the brains of Alzheimer's patients creates a blockade that shuts off genes necessary to form new memories. Furthermore, by inhibiting that enzyme in mice, the researchers were able to reverse Alzheimer's symptoms.

1 Mar 2012

Scripps Florida study to focus on four new classes of pain-relieving compounds

Scripps Florida scientists have been awarded $3.1 million by the National Institute on Drug Abuse, part of the National Institutes of Health, to study and develop several new compounds that could prove to be effective in controlling pain without the unwanted side effects common with opiate drugs, such as morphine, Oxycontin, and Vicoden.

1 Mar 2012

Inhibitory effect of serotonin 1A receptor is extremely small in people with depression

Researchers at the MedUni Vienna have, for the first time, investigated the influence of the serotonin system on the default mode network (DMN) in the human brain and discovered that, in people with depression, the inhibitory effect of the serotonin 1A receptor is extremely small. This means, says Siegfried Kasper, Head of the University Department of Psychiatry and Psychotherapy, that affected patients "are virtually never able to be mentally calm".

1 Mar 2012

LAU-0901 drug protects brain in an experimental stroke model

Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center New Orleans, has found that a synthetic molecule protected the brain in a model of experimental stroke.

29 Feb 2012

Maturitas publishes EMAS' clinical guide on SERMs against postmenopausal osteoporosis

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of an important clinical guide from the European Menopause and Andropause Society (EMAS) in the February issue of Maturitas.

29 Feb 2012

DTMI, Bristol-Myers Squibb partner to broaden interactions

Bristol-Myers Squibb Company and Duke Translational Medicine Institute (DTMI) today announced the formation of a strategic relationship to broaden interactions between the two organizations.

28 Feb 2012

TAK-875 - an emerging therapy for Type 2 diabetes

In a trial of 426 patients with Type 2 diabetes, TAK-875 reduced blood sugar below a pre-determined level in as much as 48 percent of those receiving it after 12 weeks, compared with 40 percent of those who took glimepiride, the older drug, according to findings published online by The Lancet medical journal. The research was presented in June at the American Diabetes Association’s annual meeting in San Diego.

28 Feb 2012

CNRS/Inserm researchers discover new family of anti-cancer compounds

A French-Italian team headed by researchers from CNRS and Inserm has discovered a new family of compounds that could make it possible to treat numerous cancers, particularly brain tumors and skin cancers.

28 Feb 2012

Initial stent implantation does not appear to improve outcomes for patients with stable CAD

A meta-analysis of eight previously published clinical trials suggests that initial stent implantation for patients with stable coronary artery disease is not associated with improved outcomes compared with initial medical therapy for prevention of death, nonfatal heart attacks, unplanned revascularization or angina, according to a study published in the Feb. 27 Archives of Internal Medicine, one of the JAMA/Archives journals.

28 Feb 2012

Childhood adversity may lead to epigenetic changes in glucocorticoid receptor gene

In a look at how major stressors during childhood can change a person's biological risk for psychiatric disorders, researchers at Butler Hospital have discovered a genetic alteration at the root of the association.

28 Feb 2012